Remote Assessment of Lung Disease and Impact on Physical and Mental Health (RALPMH)

University College London (UCL)

Status: Active, not recruiting

Conditions: Chronic Obstructive Pulmonary Disease; Covid19; Interstitial Lung Disease

Study type: Observational

Funder types: Other

Identifiers

NCT05630599

274070

Details and patient eligibility

About

This cohort study aims to use the open-source RADAR-base mHealth platform to collect and analyze datasets associated with lung disease. This will include continuous data collected from wearable devices (e.g. heart rate, oxygen saturation, respiratory rate), including pulse oximeters, spirometer, mobile phones, digital tests, and smart phone symptom questionnaires.

Enrollment: 60 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 20 patients with a diagnosis of COPD
• 20 patients with a diagnosis of interstitial lung disease
• 20 a clinical diagnosis of COVID-19 (within 4-13 weeks of enrolment) who either and report symptoms interfering with day to day activity present for more than 28 days following the onset of COVID-19
• Prior mobile phone use
• Willingness to use monitoring devices and complete study questionnaires.
• History of exacerbation (COPD: 2 or more exacerbations in last 1 yr)

Exclusion criteria

• Non English language Speaker
• Lack of physical capability to take part e.g. Heart Failure
• Pregnancy
• Lack of capability to consent

Trial design

60 participants in 3 patient groups

ILD

Description:

ILD, or lung fibrosis, is one of a spectrum of fibrotic diseases, associated with ageing, obesity, diabetes and pollution, that are responsible for \~45% of premature deaths in Western Europe. Of \>90,000 patients in the United Kingdom with ILD, \~30,000 have idiopathic pulmonary fibrosis, idiopathic pulmonary fibrosis, the most severe form. idiopathic pulmonary fibrosis is a disease of unknown aetiology that is more frequent in males presenting mainly in the sixth and seventh decades of life. There is no cure and median survival, just 3-5 years following diagnosis is worse than for many cancers.

COPD

Description:

COPD is a common, long term condition of the lungs that is usually caused by cigarette smoking. In addition to daily symptoms and limitations in activities, patients are prone to developing chest infections called 'exacerbations'. Exacerbations are a significant problem: unpleasant for patients, and sometimes severe enough to cause hospital admission (and therefore National Health Service pressures) and death.

COVID-19

Description:

Recovery from COVID19 has many unknowns, especially in the long term. Symptoms of COVID-19 have varied among those who have tested positive: some have displayed no symptoms, while others have developed severe pneumonia, progressing to lung injury and acute respiratory distress syndrome (ARDS) and, in the longer term, pulmonary fibrosis. Notably, the consequences of COVID-19 include effects on other organs including: heart, kidneys, and brain.